PT  - JOURNAL ARTICLE
AU  - MASAHIRO HATOOKA
AU  - TOMOKAZU KAWAOKA
AU  - HIROSHI AIKATA
AU  - KEI MORIO
AU  - TOMOKI KOBAYASHI
AU  - AKIRA HIRAMATSU
AU  - MICHIO IMAMURA
AU  - YOSHIIKU KAWAKAMI
AU  - EISUKE MURAKAMI
AU  - KOJI WAKI
AU  - YOJI HONDA
AU  - NAMI MORI
AU  - SHINTARO TAKAKI
AU  - KEIJI TSUJI
AU  - HIROTAKA KOHNO
AU  - HIROSHI KOHNO
AU  - TAKASHI MORIYA
AU  - MICHIHIRO NONAKA
AU  - HIDEYUKI HYOGO
AU  - YASUYUKI AISAKA
AU  - KAZUAKI CHAYAMA
TI  - Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
DP  - 2016 Jul 01
TA  - Anticancer Research
PG  - 3523--3529
VI  - 36
IP  - 7
4099  - http://ar.iiarjournals.org/content/36/7/3523.short
4100  - http://ar.iiarjournals.org/content/36/7/3523.full
SO  - Anticancer Res2016 Jul 01; 36
AB  - Aim: To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE). Patients and Methods: In this retrospective cohort study, 123 patients with HCC refractory to TACE, with Child-Pugh A and free of extrahepatic metastasis, were divided into two groups: 65 received HAIC and 58 received sorafenib. Since the size of main tumor and portal vein invasion were significantly different between the HAIC and sorafenib groups, we selected 48 patients from the 65 patients of the HAIC group and 48 from the 58 patients of the sorafenib group. The model used one-to-one matching between the two groups using the case–control method matching method. The clinical characteristics of patients of the case–control HAIC (n=48) and sorafenib groups (n=48) were similar. Overall survival, time to progression and time to treatment failure (TTTF) were compared between the two groups. Results: The median survival time and TTTF were significantly longer in the sorafenib group than in the HAIC group (15 and 12.2 months versus 8 and 4.4 months, respectively; p=0.021 and p=0.002, respectively). Multivariate analysis identified male gender (p=0.008), relative tumor size <50% (p=0.012), α-fetoprotein <400 ng/ml (p=0.005), and treatment with sorafenib (p=0.001) as significant and independent determinants of better overall survival. Conclusion: In patients with HCC refractory to TACE, overall survival was favorable in those treated with sorafenib rather than HAIC.